HRP20090571T1 - Farmaceutski pripravak koji sadrži cikličke analoge somatostatina - Google Patents

Farmaceutski pripravak koji sadrži cikličke analoge somatostatina

Info

Publication number
HRP20090571T1
HRP20090571T1 HR20090571T HRP20090571T HRP20090571T1 HR P20090571 T1 HRP20090571 T1 HR P20090571T1 HR 20090571 T HR20090571 T HR 20090571T HR P20090571 T HRP20090571 T HR P20090571T HR P20090571 T1 HRP20090571 T1 HR P20090571T1
Authority
HR
Croatia
Prior art keywords
ala
amino acid
pharmaceutical preparation
preparation containing
containing cyclic
Prior art date
Application number
HR20090571T
Other languages
English (en)
Croatian (hr)
Inventor
Lambert Oliver
Moser Katrin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33554159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20090571(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0314695A external-priority patent/GB0314695D0/en
Priority claimed from GB0325388A external-priority patent/GB0325388D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20090571T1 publication Critical patent/HRP20090571T1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • C07K14/6555Somatostatins at least 1 amino acid in D-form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
HR20090571T 2003-06-24 2004-06-23 Farmaceutski pripravak koji sadrži cikličke analoge somatostatina HRP20090571T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0314695A GB0314695D0 (en) 2003-06-24 2003-06-24 Organic compounds
GB0325388A GB0325388D0 (en) 2003-10-30 2003-10-30 Organic compounds
PCT/EP2004/006794 WO2005000893A2 (fr) 2003-06-24 2004-06-23 Composition pharmaceutique

Publications (1)

Publication Number Publication Date
HRP20090571T1 true HRP20090571T1 (hr) 2009-11-30

Family

ID=33554159

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090571T HRP20090571T1 (hr) 2003-06-24 2004-06-23 Farmaceutski pripravak koji sadrži cikličke analoge somatostatina

Country Status (31)

Country Link
US (3) US20070093412A1 (fr)
EP (1) EP1648934B1 (fr)
JP (1) JP4746541B2 (fr)
KR (1) KR101124136B1 (fr)
AR (1) AR044852A1 (fr)
AT (1) ATE438659T1 (fr)
AU (1) AU2004251866B2 (fr)
BR (1) BRPI0411820B8 (fr)
CA (1) CA2529449C (fr)
CL (1) CL2004001579A1 (fr)
CO (1) CO5650225A2 (fr)
CY (1) CY1109444T1 (fr)
DE (1) DE602004022420D1 (fr)
DK (1) DK1648934T3 (fr)
EC (1) ECSP056237A (fr)
ES (1) ES2328144T3 (fr)
HR (1) HRP20090571T1 (fr)
IL (1) IL172329A (fr)
IS (1) IS2705B (fr)
MA (1) MA27862A1 (fr)
MX (1) MXPA05013821A (fr)
MY (1) MY145375A (fr)
NO (1) NO330706B1 (fr)
NZ (1) NZ544157A (fr)
PE (1) PE20050285A1 (fr)
PL (1) PL1648934T3 (fr)
PT (1) PT1648934E (fr)
RU (1) RU2355418C2 (fr)
SI (1) SI1648934T1 (fr)
TW (1) TWI361194B (fr)
WO (1) WO2005000893A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100273719A1 (en) 2007-11-28 2010-10-28 Novartis Ag Use of somatostatin analogs in meningioma
KR101500528B1 (ko) * 2007-12-03 2015-03-09 이탈파마코 에스.피.에이. 새로운 비-선택적 소마토스타틴 유사체
FR2942227B1 (fr) * 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
TWI633887B (zh) 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物
BR112016007078A2 (pt) * 2013-09-30 2017-12-12 Ono Pharmaceutical Co composto tendo atividade agonística do receptor de somatostatina e uso farmacêutico do mesmo
CN104447962B (zh) * 2014-12-29 2018-07-17 成都圣诺生物科技股份有限公司 一种合成帕瑞肽的方法
GB201816637D0 (en) * 2018-10-12 2018-11-28 Heptares Therapeutics Ltd Selective somatostatin receptor agonists
TWI764248B (zh) * 2019-08-23 2022-05-11 大陸商四川海思科製藥有限公司 肽醯胺類組合物及其製備

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1276839A (en) * 1968-08-02 1972-06-07 Sandoz Products Ltd Antibiotic compositions
US4328214A (en) * 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
ATE14226T1 (de) * 1981-12-24 1985-07-15 Ciba Geigy Ag Cyclische octapeptide und pharmazeutische praeparate davon, sowie verfahren zur herstellung derselben und ihre anwendung.
US4612366A (en) * 1985-06-17 1986-09-16 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
DE3822557C2 (de) * 1987-07-10 1998-07-02 Ciba Geigy Ag Arzneimittel, enthaltend Somatostatine
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
JPH02111A (ja) * 1987-08-03 1990-01-05 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド製剤
JP2641755B2 (ja) 1988-01-29 1997-08-20 住友製薬株式会社 コントロールリリース製剤
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
WO1995000553A1 (fr) 1993-06-23 1995-01-05 Diatech, Inc. Peptides radiomarques derives de la somatostatine et utilises dans des procedes d'imagerie et therapeutiques
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
ES2167189B1 (es) 1999-12-17 2003-04-01 Lipotec Sa Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
ES2399651T3 (es) * 2008-07-08 2013-04-02 Novartis Ag Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena

Also Published As

Publication number Publication date
SI1648934T1 (sl) 2010-01-29
CL2004001579A1 (es) 2005-05-20
BRPI0411820B8 (pt) 2021-05-25
EP1648934B1 (fr) 2009-08-05
AR044852A1 (es) 2005-10-05
IS2705B (is) 2010-12-15
AU2004251866A1 (en) 2005-01-06
IS8247A (is) 2006-01-20
NO330706B1 (no) 2011-06-20
CA2529449C (fr) 2012-05-15
HK1089776A1 (en) 2006-12-08
JP2007536195A (ja) 2007-12-13
RU2006101720A (ru) 2007-08-10
PT1648934E (pt) 2009-10-23
BRPI0411820A (pt) 2006-08-08
MA27862A1 (fr) 2006-04-03
DE602004022420D1 (de) 2009-09-17
TW200514789A (en) 2005-05-01
US8299209B2 (en) 2012-10-30
PE20050285A1 (es) 2005-06-09
BRPI0411820B1 (pt) 2019-06-25
US20130035286A1 (en) 2013-02-07
US20090137462A1 (en) 2009-05-28
IL172329A0 (en) 2009-02-11
ATE438659T1 (de) 2009-08-15
AU2004251866B2 (en) 2008-06-12
ECSP056237A (es) 2006-04-19
NZ544157A (en) 2008-07-31
WO2005000893A3 (fr) 2005-04-07
IL172329A (en) 2013-12-31
KR20060030052A (ko) 2006-04-07
CO5650225A2 (es) 2006-06-30
NO20060375L (no) 2006-01-24
MXPA05013821A (es) 2006-02-28
KR101124136B1 (ko) 2012-03-21
DK1648934T3 (da) 2009-10-26
EP1648934A2 (fr) 2006-04-26
PL1648934T3 (pl) 2010-01-29
CY1109444T1 (el) 2014-08-13
WO2005000893A2 (fr) 2005-01-06
ES2328144T3 (es) 2009-11-10
JP4746541B2 (ja) 2011-08-10
MY145375A (en) 2012-01-31
RU2355418C2 (ru) 2009-05-20
TWI361194B (en) 2012-04-01
CA2529449A1 (fr) 2005-01-06
US20070093412A1 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
BR9609335B8 (pt) Análogos de somatostatina, bem como composição farmacêutica compreendendo os mesmos.
DK150146B (da) Analogifremgangsmaade til fremstilling af somatostatinanaloge hepta- eller octapeptider eller salte eller complexer deraf
DE60233137D1 (de) Transporter mit beabstandeten arginin-teilchen
DK1660528T3 (da) Mutein af tåre-lipocalin
ES2150983T3 (es) Productos proteicos bactericidas estables que incrementan la permeabilidad y composiciones farmaceuticas que los contienen.
YU39695A (sh) Formulacija analoga insulina
DE69027989D1 (de) Il-3 MIT ZUSÄTZLICHEN CYSTEINRESTEN UND CHEMISCHE MODIFIKATIONEN DAVON
DE50107705D1 (de) Neue pharmazeutische zusammensetzung zur verabreichung von n-0923
TW200631592A (en) Soluble, stable insulin-containing formulations
ATE345810T1 (de) Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend polypeptide
ATE489462T1 (de) Antimikrobielles polypeptid und nutzung davon
RU2006120484A (ru) Микрочастицы, содержащие аналоги соматостатина
ATE364079T1 (de) Peptide mit gdp-austauschfaktorartiger wirkung, dafür kodierende nukleinsäuresequenzen, ihre herstellung und verwendung
EA200000378A1 (ru) Усеченные по амино-концу мср-2 как антагонисты хемокинов
WO2007135117A3 (fr) Formulations solubles stables contenant de l'insuline
ATE211391T1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
SE9101838D0 (sv) Novel peptides and their use
ATE455792T1 (de) Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
MY147920A (en) Antibacterial and antiviral peptides from actinomadura namibiensis
WO2005004899A3 (fr) Substances a activite biologique du peptide intestinal vasoactif pour le traitement d'affections pulmonaires interstitielles
AR004497A1 (es) Un análogo hexapéptido cíclico de somatostatina, procedimiento para prepararlos y las composiciones farmacéuticas que los contienen y el uso de dicho hexapéptido para la preparación de una composición farmacéutica.
AR044852A1 (es) Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
PL1648924T3 (pl) Dipeptydowe inhibitory transglutaminaz i sposoby ich stosowania
DE60237784D1 (de) Verfahren zur verabreichung eines thymosin-alpha 1 peptids
DK1506295T3 (da) Muteiner af placental vækstfaktor type 1, fremstillingsfremgangsmåde og anvendelser deraf